Fig. 4.
Results of MLAEP Nb latencies (A) and Nb-Pa amplitudes (B) and of electroencephalographic PeEn during stimulation (C, E, G) and without stimulation (D, F, H). Boxplots are illustrated for each drug (in sequence of propofol [red], sevoflurane [blue], remifentanil [green], and (s)-ketamine [purple]) and for each concentration level I–III. AEP = auditory evoked potential; CHEP = contact heat–evoked potential; MLAEP = mid-latency auditory evoked potential; PeEn = permutation entropy; VPEP = visceral pain–evoked potential; I = baseline without any drug application; II = drug concentration level II (propofol: 0.5 μg/ml, remifentanil 0.05 μg·kg−1·min−1, (s)-ketamine 0.25 mg·kg−1·h−1, and sevoflurane: 0.40 vol%); III: drug concentration level III (propofol: 1.0 μg/ml, remifentanil 0.15 μg·kg−1·min−1, (s)-ketamine 0.5 mg·kg−1·h−1, and sevoflurane: 0.80 vol%).

Results of MLAEP Nb latencies (A) and Nb-Pa amplitudes (B) and of electroencephalographic PeEn during stimulation (C, E, G) and without stimulation (D, F, H). Boxplots are illustrated for each drug (in sequence of propofol [red], sevoflurane [blue], remifentanil [green], and (s)-ketamine [purple]) and for each concentration level I–III. AEP = auditory evoked potential; CHEP = contact heat–evoked potential; MLAEP = mid-latency auditory evoked potential; PeEn = permutation entropy; VPEP = visceral pain–evoked potential; I = baseline without any drug application; II = drug concentration level II (propofol: 0.5 μg/ml, remifentanil 0.05 μg·kg−1·min−1, (s)-ketamine 0.25 mg·kg−1·h−1, and sevoflurane: 0.40 vol%); III: drug concentration level III (propofol: 1.0 μg/ml, remifentanil 0.15 μg·kg−1·min−1, (s)-ketamine 0.5 mg·kg−1·h−1, and sevoflurane: 0.80 vol%).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal